Netupitant and Palonosetron
Reading tools
Approved by the FDA on 10 October 2014, Akynzeo is a supportive medicine combining two drugs to treat chemotherapy-related nausea and vomiting. Netupitant acts through Substance P, involved in pain, while Palonosetron acts at the binding site of the molecule 5HT3(serotonin).
Akynzeo offers an advantage in preventing nausea and vomiting, side effects that can begin abruptly or occur later in chemotherapy patients. It causes the general side effects associated with most cancer drugs.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.